These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 15546153)

  • 1. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins.
    Edison RJ; Muenke M
    Am J Med Genet A; 2004 Dec; 131(3):287-98. PubMed ID: 15546153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes.
    Taguchi N; Rubin ET; Hosokawa A; Choi J; Ying AY; Moretti ME; Koren G; Ito S
    Reprod Toxicol; 2008 Oct; 26(2):175-7. PubMed ID: 18640262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teratogenic risk of statins in pregnancy.
    Godfrey LM; Erramouspe J; Cleveland KW
    Ann Pharmacother; 2012 Oct; 46(10):1419-24. PubMed ID: 23032657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
    McAdams M; Staffa J; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2007 Feb; 99(3):379-81. PubMed ID: 17261402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin-associated memory loss: analysis of 60 case reports and review of the literature.
    Wagstaff LR; Mitton MW; Arvik BM; Doraiswamy PM
    Pharmacotherapy; 2003 Jul; 23(7):871-80. PubMed ID: 12885101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
    Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study.
    Winterfeld U; Allignol A; Panchaud A; Rothuizen LE; Merlob P; Cuppers-Maarschalkerweerd B; Vial T; Stephens S; Clementi M; De Santis M; Pistelli A; Berlin M; Eleftheriou G; Maňáková E; Buclin T
    BJOG; 2013 Mar; 120(4):463-71. PubMed ID: 23194157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin.
    Pollack PS; Shields KE; Burnett DM; Osborne MJ; Cunningham ML; Stepanavage ME
    Birth Defects Res A Clin Mol Teratol; 2005 Nov; 73(11):888-96. PubMed ID: 16163683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin drugs and congenital anomalies.
    Gibb H; Scialli AR
    Am J Med Genet A; 2005 Jun; 135(2):230-1; author reply 232-4. PubMed ID: 15810007
    [No Abstract]   [Full Text] [Related]  

  • 13. Statins: beware during pregnancy.
    Prescrire Int; 2006 Feb; 15(81):18-9. PubMed ID: 16548110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs.
    Akimoto H; Negishi A; Oshima S; Okita M; Numajiri S; Inoue N; Ohshima S; Kobayashi D
    Pharmacol Res Perspect; 2018 Dec; 6(6):e00439. PubMed ID: 30443347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
    Smith DG; McBurney CR
    Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study.
    Dave CV; Winterstein AG; Park H; Cook RL; Hartzema AG
    J Affect Disord; 2018 Oct; 238():542-546. PubMed ID: 29936394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological interactions of statins.
    Paoletti R; Corsini A; Bellosta S
    Atheroscler Suppl; 2002 May; 3(1):35-40. PubMed ID: 12044584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of maternal toxicity in lovastatin-induced developmental toxicity.
    Lankas GR; Cukierski MA; Wise LD
    Birth Defects Res B Dev Reprod Toxicol; 2004 Jun; 71(3):111-23. PubMed ID: 15282732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal exposure to statins and risk for birth defects: a case-series approach.
    Petersen EE; Mitchell AA; Carey JC; Werler MM; Louik C; Rasmussen SA;
    Am J Med Genet A; 2008 Oct; 146A(20):2701-5. PubMed ID: 18792975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.